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Abstract
Background/Aim. Morbidity and mortality of continous
ambulatory peritoneal dialysis (CAPD) patients is still very
high. The aim of the study was to evaluate the effects of
peritoneal dialysis (PD) solutions (standard vs biocompatible)
on long-term patients’ and the techique survival. Methods. A
total of 42 stable patients on CAPD participated in this cross-
sectional study. They were prospectively followed-up during
the twelve years. Patients with severe anemia (Hb < 10 g/L)
and malignant disease ware excluded. Twenty one (50%) pa-
tients were treated with the standard PD solutions (CAPDP-
1) while the other 21 (50%) were treated with biocompatible
PD solutions [(lower level of glucose degradation products,
lower concentration of Ca2+ and neutral pH (CAPDP-2)]. All
patients were analyzed for a presence of vascular calcification,
nutrition status, and parameters of inflammation after 2.5 ±
0.6 years of starting CAPD, and these variables considered in
the analysis as risk factors. Results. The patients from the
group CAPDP-2 compared to those from the group
CAPDP-1 had lower level of high-sensitivity C-reactive pro-
tein (hs-CRP) (p = 0.003), and better nutritional status as con-
firmed by the mid-arm circumference (p = 0.015), and mid-
arm muscle circumference (p = 0.002) and subjective global
assessment (p = 0.000). Also, they had lower vascular calcifi-
cations as confirmed by intima media thickness (IMT) (p =
0.003), degree of carotid narrowing (p = 0.001) and calcified
plaques of common carotid arteries (CCA) (p = 0.008). Kap-
lan-Meier analysis confirmed better survival of patients from
the group CAPDP-2 than those from the group CAPDP-1
(1-, 5-, and 10-year patients survival rate was: 100%, 61.9%
and 14.3% for the group CAPDP-1, and 100%, 85.7%, and
52.4% for the group CAPDP-2, respectively; p = 0.0345).
The 1-, 5-, and 10-year technique survival rate was: 100%,
71.4%, and 38.1% for the group CAPDP-1, and 100%,
85.7%, and 76.2% for the group CAPDP-2, respectively; (p =
0.0719). Duration of dialysis, serum triglyceride and cardio-
vascular score (quantitative scoring system consisting of:
ejection fraction (EF) of left ventricle < 50%; IMT > 1 mm;
carotid narrowing degree > 50%, presence of carotid plaques
in both common carotide, ischaemic heart disease, cerebro-
vascular event and peripheral vascular disease with or without
amputation) were independent predictors of overall patient
survival. Duration of dialysis was only independent predictor
of overall technique survival. Conclusion. Although patients
treated with biocompatible solutions showed significantly
better survival, the role of biocompatibility of CAPD solu-
tions in patients and technique survival have to be confirmed.
Namely, multivariate analysis confirmed that duration of di-
alysis, serum triglyceride and cardiovascular score significantly
predicted overall CAPD patients survival, while only duration
of dialysis was found to be independent predictor of overall
techique survival.
Key words:
peritoneal dialysis,  continuous ambulatory; survival
analysis; dialysis solutions; morbidity; mortality; risk
factors.
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Apstrakt
Uvod/Cilj. Morbiditet i mortalitet bolesnika na kontinuira-
noj ambulantnoj peritoneumskoj dijalizi (KAPD) i dalje je
neprihvatljivo visok. Cilj rada bio je da se proceni uticaj vr-
ste dijaliznih rasvora (bioinkompatibilni vs biokompatibilni)
na višegodišnje preživljavanje bolesnika i same tehnike
KAPD. Metode. Ovom studijom preseka sa delimi?no pro-
spektivnim pra?enjem ishoda le?enja obuhva?eno je ukupno
42 nasumice izabrana, stabilna bolesnika (26 muškaraca i 16
žena) le?ena primenom metode KAPD tokom poslednjih
12 godina. Isklju?eni su bolesnici sa teškom anemijom (Hb
<10 g/L) i malignom boleš?u. Pri tome, 21 (50%) bolesnika
kontinuirano je le?eno bioinkompatibilnim rastvorom za
KAPD (kiseli standardni rastvor – ANDY-disc; grupa
KAPDB-1), dok je preostalih 21 bolesnik sve vreme bilo na
biokompatibilnijem rastvoru za KAPD (neutralni rastvor sa
znatno manjom koncentracijom degradacionih produkata
glukoze, 1.25 mmol/L Ca i 40 mmol/L laktata – Gambro-
sol Trio; grupa KAPDB-2). Svim bolesnicima odre?eni su
odabrani parametri hroni?ne inflamacije, malnutricije i ate-
roskleroze zajedno sa transportnim karakteristikama perito-
neumske membrane i rezidualnom bubrežnom funkcijom
nakon  2,5 ± 0,6 god od zapo?injanja KAPD. Svi dobijeni
rezultati analizirani su kao potencijalni faktori rizika. Re-
zultati. Grupa KAPDB-2 u odnosu na KAPDB-1 imala je
statisti?ki zna?ajno niže vrednosti serumskog hs-CRP (p =
0,003) i bolje parametre nutritivnog statusa izražene kroz
obim nadlaktice (p = 0,015), obim miši?a nadlaktice (p =
0,002) i subjektivnu globalnu procenu (p = 0,000) kao i u
manjoj meri prisutnu aterosklerozu potvr?eno debljinom
intimomedijalnog kompleksa (IMT) (p = 0,003), stepenom
suženja karotida (p = 0,001) i prisustvom kalcifikovanih ate-
romatoznih plakova na karotidnim arterijama (p = 0,008).
Kaplan-Meier-ova kriva preživljavanja potvrdila je zna?ajno
duže preživljavanje bolesnika u grupi KAPD-2 u odnosu na
KAPDB-1 (1-, 5-, i 10-godišnje preživljavanje bolesnika iz-
nosilo je redom: 100%, 61.9% i 14.3% u KAPDB-1, a
100%, 85,7% i 52,4% u KAPDB-2 grupi; p = 0,0345). Stopa
1-, 5-, i 10-godišnjeg preživljavanja metode iznosila je:
100%, 71,4% i 38,1% u KAPDB-1, a 100%, 85,7% i 76,2%
u KAPDB-2 grupi (p = 0,0719). Kao nezavisni prediktori
opšteg preživljavanja bolesnika na KAPD izdvojili su se:
dijalizni staž, nivo serumskih triglicerida i skor kardiovasku-
larnog morbiditeta (kvantitativni sistem zbrajanja prisutnih
slede?ih parametara: ejekciona frakcija (EF) leve komore
< 50%;  IMT >1 mm;  suženje lumena karotida > 50%; kal-
cifikovani ateromatozni plakovi na obe karotide; ishemijska
bolest srca; cerebrovaskularni doga?aj i periferna vaskularna
bolest sa ili bez gangrene). Kao nezavisan prediktor preživ-
ljavanja metode izdvojio se jedino dijalizni staž. Zaklju?ak.
Iako su bolesnici na KAPD sa biokompatibilnijim rastvori-
ma pokazali statisti?ki zna?ajno bolje preživljavanje, ne mo-
žemo tvrditi da bioinkompatibilnost dijaliznih rastvora
predstavlja zna?ajan faktor rizika od preživljavanja bolesnika
i same metode le?enja. Naime, multivarijantnom analizom
kao prediktori opšteg preživljavanja bolesnika izdvojili su se
samo dijalizni staž, nivo serumskih triglicerida i skor kardio-
vaskularnog morbiditeta, dok  se za o?uvanje peritoneumske
membrane kao nezavisan faktor rizika prikazao samo dijali-
zni staž.
Klju?ne re?i:
dijaliza, peritoneumska, ambulantna, kontinuirana;
preživljavanje, analiza; rastvori, dijalizni; morbiditet;
mortalitet; faktori rizika.
Introduction
Continuous ambulatory peritoneal dialysis (CAPD)
has been a successful modality of renal replacement ther-
apy for more than 30 years. CAPD, similarly to hemodyali-
sis (HD), has unsatisfactory mortality rate despite of all
improvement of techniques that were described over the
past decades 1. The reason for high mortality is probably
multifactorial: older age, co-morbidity, inflammation, mal-
nutrition and atherosclerosis (MIA syndrome), decline in
residual renal function (RRF) and increased peritoneal
transport characteristics 2, 3. Several reports in the literature
suggest that racial and geographic difference may influence
patients survival in dialysis populations 2. Centre and pa-
tients characteristics may differ between study populations,
and this may explain different literature reports. It is im-
portant to evaluate all predictors of patients and technique
survival since correction of such risk factors may decrease
morbidity and mortality and promote better quality of life
in CAPD patients.
Annual morbidity rate of CAPD patients is more than
20% 4, 5, out of which 60% of patients die due to cardiovas-
cular diseases (CVD) 6–8. Progressive atherosclerosis signifi-
cantly affect CV morbidity and mortality: 30%–60% of them
suffer from calcification of hearth valves, while 70%–90% of
patients suffer from calcification of coronary arteries 9–13.
Both prevalence and extent of calcification predicts CVD
and total mortality in CAPD patients. It is also well known
that MIA syndrome is an important predictors of mortality in
PD patients 3, 14–16.
Recent developments in PD solution were aimed to im-
prove their biocompatibility by changing buffers, osmotic
agents and sterilization techniques, thereby reducing toxic ef-
fects on the immune system and functional deterioration of
the peritoneal membrane 17. Still, PD maintains a constant
state of intraperitoneal inflammation which affects peritoneal
membrane and has the potential to affect the efficiency of
each PD dwell 18–21.
Currently, there are not many data on the effects of bio-
compatible solutions on survival. The long-term effects of
pH neutral PD solutions that are low in glucose degradation
products (GDP) are not clear. They seem to better preserve
the peritoneal membrane and have less systemic effects than
the conventional ones. Most of recent studies had a short
follow-up (of only 6–12 months) for the confirmation of the
effects of new biocompatible PD solutions on peritoneal
transport, technique and patients survival 22.
The aim of the study was to evaluate a potential influ-
ence of biocompatibility of dialysis solutions on long-term
CAPD patients and the techique survival.
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Methods
This single-center cross-sectional study with prospec-
tive follow-up of the outcomes was performed in the Mili-
tary Medical Academy Belgrade, where patients were
treated by CAPD according to the mode of insurance: bio-
compatible PD solutions were covered by military insur-
ance while patients with civil insurance were treated with
bioincompatible PD solutions from the first PD start. The
patients with military insurance were rarely officers (n = 5)
but the members of their families (spouse, offspring). Pre-
end stage renal disease (ESRD) treatment was not depend-
ent on the type of insurance and those who had military in-
surance had all other access to medical care except of more
expensive biocompatible CAPD solutions once when they
reached ESRD.
The study included 42 stable randomly selected CAPD
patients from both groups (26 men and 16 women) during
the twelve years. Those with severe anemia (Hb < 10 g/L),
history of or current systemic inflammatory disease or im-
munomodulatory therapy and malignant disease were ex-
cluded. Twenty one (50%) patients were treated with the
standard bioincompatible  PD solutions [conventional glu-
cose-based, lactate-buffered solutions – Stay safe, ANDY-
disc; Fresenius Medical Care, (the CAPDP-1 group)] while
the remaining 21 (50%) of the patients were treated with bio-
compatible PD solutions [lower level of glucose degradation
products (GDPs), lower concentration of  Ca2+ and neutral
pH – Fresenius Medical Care Stay Safe balance; Gambrosol
Trio, (the CAPDP-2 group)]. There was no switch-over be-
tween modalities. There were no significant differences in
prescription of statins, aspirin, erythropoietin, vitamin D and
iron between the groups from starting CAPD until the time
of analysis.
After 2.5 ± 0.6 years of CAPD starting, all the patients
underwent echocardiography and B-mode ultrasonography
of common carotid arteries CCA together with assessments
of nutrition status, residual renal function, peritoneal solute
transport and some biochemical parameters of systemic and
local inflammation, and these variables were considered in
the analysis of risk factors.
Data including age, gender and underlying renal disease
were analyzed at the moment of starting CAPD. Data in-
cluding residual renal function and peritoneal solute trans-
port were observed after 2.5 ± 0.6 years of starting CAPD
and were correlated with the presence of chronic inflamma-
tion, echocardiography data, B-mode ultrasonography of
CCA data, parameters of malnutrition, peritoneal transport
and cardiovascular score (CVS) which were determined after
the same period of beginning on CAPD. The end-points of
the study were patients death, transplantation, transfer to HD
or the end of the study period in April 2009.
Residual renal function was estimated by measuring 24
h urine collection (residual diuresis) and serum level of a
novel serum marker of the glomerular filtration rate – cys-
tatin C by particle-enhanced nephelometric immunoassay
(Dade-Behring's). Cystatin C in PD fluid was not measured.
The normal average reference range of serum Cystatin C for
patients without renal failure was 0.52–0.90 mg/L for
women, and 0.56–0.98 mg/L for men.
High-sensitivity C-reactive protein (Hs-CRP) as acute-
phase parameters of systemic inflammation, was measured
by using the Tina-quant CRP (Latex) highly sensitive assay
(Roche Diagnostics GmBH, Mannheim, Germany). The
lower limit of detection for hs-CRP 0.01 mg/L. CRP values
less than 5 mg/L was considered normal. A fasting venous
blood samples were taken from the subjects before the
morning exchange after a 12 h our fasting.
Effluent concentration of CA-125 as a marker of
mesothelial cell mass and pro-inflammatory cytokine inter-
leukin (IL)-6 as a marker of local inflammation were meas-
ured in overnight effluent in both groups of CAPD patients.
Dialysate samples were taken immediately after the dwell.
The effluent Ca-125 concentration was measured using an
electrochemoluminescence immunoassay (CECLIA) (Lecsys
2010; Roche Diagnostics, Heidelberg, Germany), the sensi-
tivity of which was 0.60 U/mL. The effluent CA-125 con-
centrations greater than 35 U /mL were considered as a good
values.
Peritoneal level of IL-6 was determined by specific
commercial ELISA kits (Biosource, Camarillo, CA, USA).
The lowest threshold of detectability for IL-6 was 2 pg/mL.
The nutritional status of patients was assessed by meas-
urement of serum albumin, total cholesterol and triglycer-
ides, body mass index (BMI), anthropometric parameters and
by subjective global assessments (SGA). Body mass index
was calculated by the equation published elsewhere 23.
Anthropometric measurements included mid-arm cir-
cumference (MAC), triceps skinfold (TSF), and a calculated
estimate of the mid-arm muscle circumference (MAMC) ac-
cording to NKF K/DOQI Guidelines 23, 24. SGA was based on
methodology described by Kalantar-Zadeh et al. 24. The data
were weighed and the patients were classified in terms of
three major SGA scores: 1 = well nourished, 2 = moderate
malnutrition or 3 = severe malnutrition.
Peritoneal solute transport was investigated by perito-
neal equilibration test (PET) and by measuring 24-h perito-
neal ultrafiltration (UF, ml) using standard method described
by Twardowski 25 .
Echocardiography measurements were made by a single
experienced cardiologist according to the recommendations
of the American Society of Echocardiography 26 with Aspen-
ACUSON device equipped with a 2.5 MHz probe. Cardiac
valvular calcification was defined as bright echoes of >1 mm
on one or more cusps of the aortic valve, mitral valve or mi-
tral annulus.
B-mode ultrasonography of CCA was performed by
using the ALOCA SSD 2000 system equipment with 7.5
MHz linear transducers. A trained sonographer evaluated in-
tima-media thickness (IMT, mm), carotid narrowing degree
(%) and the presence of carotid plaques in both CCAs 4 cm
from the bulbs, within carotid bulbs and the first 2 cm of the
internal and external carotid arteries. Plaques were defined as
echogenic structures showing protrusion into the lumen with
focal widening that was 50% greater than the IMT of ad-
jancent sites. Highly echogenic plaques producing bright
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white echoes with shadowing were considered to be calcifi-
cations. Such plaques were defined as representing arterial
intimal calcification pattern.
Cardiovascular score included: ejection fraction (EF) of
left ventricle < 40%; IMT > 1 mm; carotid narrowing degree
> 50%, the presence of carotid plaques in both common ca-
rotide, ischemic heart disease, cerebrovascular event and pe-
ripheral vascular disease with or without amputation. The
cardiovascular morbidity score for each patient was defined
as the number of these domains affected, varying from score
0 to score 7.
Patients outcome included a reason of death: cardiovas-
cular diseases (ishemic heart disease, cerebrovascular disease
and peripherial vascular disease) and noncardiovascular dis-
eases (peritonitis, multiorgan failure).
Patients survival analysis included data from the start of
CAPD until the end of the follow-up period in April 2009 or
date of death, censored at the time of renal transplantation
and transfer to hemodialysis.
Technique survival analysis included data from the start
of CAPD until the date of transfer to HD or at the end of a
follow-up period in April 2009, censored at the time of renal
transplantation and date of patients death.
Statistical calculations were performed using the SPSS
software program. Data were expressed as percentages for
discrete factors, and mean values for continuous variables.
Medians were used for continues variables without normal
distribution. Student's t-test (parametric data) and Kruscal
Wallis test or Mann-Whitney (non-parametric data) were
used to compare the subgroups. The ?2 test was used to com-
pare the nominal variables between different subgroups.
Acturial survival rates were determined by the Kaplan-Meier
method. A log-rank test was used to compare the patient and
technique survival between the subgroups. The Cox propor-
tional hazards model was used to identify the factors pre-
dicting patient mortality and technique survival. The Cox
model for multivariate analysis was constructed by those
factors significant at univariate analysis. In all the compari-
sons, a p value < 0.05 was considered statistically significant.
Results
In this paper we analyzed the patients divided in two
groups according to the type of insurance. Even so, the se-
lection bias was avoided since there were no significant dif-
ferences between the groups in age, gender, underlying renal
disease, residual renal function, ultrafiltration and peritoneal
transport characteristics (Table 1). In addition, there were no
differences between groups in comorbidity and previous
medication [(including erythropoietin stimulating agents, an-
giotensin-converting enzyme (ACE) inhibitors, iron and vi-
tamin D, social status and monthly income (data not
shown)].
At the moment of analysis (after 2.5 ± 0.6 years of
starting CAPD) inflammatory markers in the serum and in
peritoneal effluent were analyzed (Table 2). The mean value
of serum hs-CRP was significantly lower in the CAPDP-2
than in the CAPDP-1 group, while there were no significant
differences between the groups concerning the effluent level
of IL-6 and CA-125.
Nutritional parameters are presented in Table 3. There
were no significant differences between the groups in total
serum cholesterol, triglyceride, albumin and BMI. By com-
paring mid-arm circumference, mid-arm muscle circumfer-
Table 1
General characteristics of the examined patients at the moment of analysis [age, gender and underlying renal disease at the
moment of starting continuous ambulatory peritoneal dialysis (CAPD)]; other 2.5 ± 0.6 yearsfollowingstarting CAPD)
The examined groupsThe observed parameters CAPDP-1 CAPDP-2 p-value
Number of patients 21 21 /
Average age (years), ? ± SD 60.5 ± 13.7 65.8 ± 12.2 NS
11 (52.4) 15 (71.4)
Gender, n (%)
male
female 10 (47.6) 6 (28.6)
NS
7 (33.3) 8 (38.1)
2 (9.5) 2 (9.5)
8 (38.1) 10 (47.6)
2 (9.5) 0 (0)
1 (4.8) 1 (4.8)
Cause of CRF, n (%)
diabetic nephropathy
chronic GN
nephroangiosclerosis
BEN
nephrolithiasis
unknown 1 (4.8) 0 (0)
NS
Residual diuresis (L/day), ? ± SD 0.64 ± 0.72 0.65 ± 0.59 NS
Cystatin C (mg/L), ? ± SD 6.23 ± 1.62 5.36 ± 1.31 NS
3 (14.3) 5 (23.8)
9 (42.9) 12 (57.1)
7 (33.3) 3 (14.3)
Peritoneal transport, n (%)
low
low average
high average
high 2 (9.5) 1 (4.8)
NS
Ultrafiltration volume (mL/24h), ? ± SD 938.1 ± 563.0 892.2 ± 598.7 NS
CAPDP-1 – the group of patients treated by bioincompatible peritoneal dialysis solutions;
CAPDP-2 – the group of patients treated by biocompatible peritoneal dialysis solutions; CRF – chronic renal failure;
GN –  glomerulonephritis; BEN – Balkan endemic nephropathy;  rGFR – residual glomerular  filtration rate; NS – not significant
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ence and subjective global assessment it was confirmed that
the patients from the CAPDP-1 group had significantly
worse nutritional status than those from the CAPDP-2 group.
Cardiovascular scores are presented in Table 4. Both
groups of the patients had mean EF, in the normal range.
Although the patients on CAPDP-1 solutions had higher fre-
quency of valvular calcification, the difference between
groups did not reach statistical significance. Significant dif-
ferences between groups were observed in prevalence of left
ventricular hypertrophy (LVH), CVS, IMT, the degree of ca-
rotid narrowing and calcified plaques of CCA.
Clinical outcome is shown in Table 5. At the end of
follow-up, 57.1% of the patients in the CAPDP-1 group and
47.7% in the CAPDP-2 group died. The most frequent
causes of death were cardiovascular diseases in both groups
without a statistical significance.
Patients and technique survival rates are shown in Fig-
ures 1 and 2. By Kaplan-Meier analysis, it was revealed that
patients who underwent CAPD by bioincompatible PD solu-
tions had significantly lower survival than  those on CAPD by
more biocompatible solutions. The median duration of treat-
ment (from the start of CAPD to the end of follow up period)
Table 2
Biochemical markers of inflammation for the examined patients at the moment of analysis (2.5 ± 0.6 years
following starting continuous ambulatory peritoneal dialysis – CAPD)
The examined groupsThe observed parameters CAPDP-1 CAPDP-2 p-value
Markers of systemic inflammation
hs-CRP (mg/L), ? ± SD (median) 6.3 ± 4.5 (5.31) 3.7 ± 2.6 (3.53) 0.003
Markers of local inflammation
effluent IL-6 (pg/mL), ? ± SD (median) 135.6 ± 114.1 (84.8) 117.3 ± 79.8 (80.0) NS
effluent CA-125 (U/mL), ? ± SD (median) 30.3 ± 21.8 (24.04) 42.7 ± 32.4 (31.6) NS
CAPDP-1– the group of patients treated by bioincompatible peritoneal dialysis solutions; CAPDP-2 – the group of patients treated by biocompatible peritoneal
dialysis solutions; hs-CRP – high-sensitivity C-reactive protein; NS – not significant
Table 3
Nutritional parameters for the examined groups of patients at the time of analysis (2.5 ± 0.6 years
folloving starting continuous ambulatory peritoneal dialysis –  CAPD)
The examined groupsThe observed parameters CAPDP-1 CAPDP-2 p-value
Serum albumin (g/L), ? ± SD (median) 30.2 ± 4.1 (30.0) 30.2 ± 3.7 ( 30.0) NS
Serum total cholesterol (mmol/L), ? ± SD (median) 6.1 ± 1.4 (5.83) 5.4 ± 1.3 (5.41) NS
Serum triglycerides (mmol/L), ? ± SD (median) 2.4 ± 1.3 (2.1) 2.4 ± 1.6 (1.92) NS
Body mass index (kg/m2), ? ± SD (median) 24.8 ± 4.0 (25.05) 24.6 ± 1.9 ( 24.32) NS
MAC (cm), ? ± SD (median) 27.9 ± 4.0 (27.0) 28.4 ± 2.4 (29.5) 0.015
MAMC (cm), ? ± SD (median) 22.7 ± 2.4 (22.3) 23.1 ± 2.9 (24.2) 0.002
Subjective global assessment, n (%)
well nourished 6 (28.6) 18 (85.7)
mildly malnourished 10 (47.6) 3 (14.3)
moderate to severe malnutrition 5 (23.8) 0 (0)
0.000
CAPDP-1 – the group of patients treated by bioincompatible peritoneal dialysis solutions; CAPDP – the group of patients treated by biocompatible peritoneal
dialysis solutions; MAC – mid-arm circumference; MAMC – mid-arm muscle circumference; NS – not significant
Table 4
Markers of cardiovascular morbidity for the examined patients at the moment of analysis (2.5 ± 0.6 years
following starting CAPD)
The examined groupsThe observed parameters CAPDP-1 CAPDP-2 p value
IMT (mm), ? ± SD 1.6 ± 0.5 1.2 ± 0.3 p = 0.005
Carotid narrowing degree (%), ? ± SD 32.4 ± 16.5 12.9 ± 14.9 p = 0.000
Presence of calcified plaques, n (%) 20 (95.2) 13 (61.9) p = 0.003
Ejection fraction (%), ? ± SD 57.1 ± 7.1 59.9 ± 3.6 NS
Presence  of LVH, n (%) 19 (90.5) 13 (61.9) p = 0.039
Presence of valvular calcification, n (%) 15 (71.4) 9 (42.9) NS
1 (4.8) 1 (4.8)
0 (0) 4 (19.0)
3 (14.3) 7 (33.3)
5 (23.8) 6 (28.6)
10 (47.6) 3 (14.3)
2 (9.5) 0 (0)
0 (0) 0 (0)
CVS, n (%)
0
1
2
3
4
5
6
7 0 (0) 0 (0)
p = 0.012
CAPDP-1 – the group of patients treated by bioincompatible peritoneal dialysis solutions; CAPDP-2 – the group of patients treated by biocompatible
peritoneal dialysis solutions; IMT – intima-media thickness; LVH – left ventricular hypertrophy; CVS – cardiovascular score (see the text); NS – not
significant
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for the CAPDP-1 group was 78 months (range 30 to 128
months) while the median duration of the treatment for the
CAPDP-2 group was 128 months (range 32 to 144 months).
Technique survival rate was not different between the
groups (Figure 2). The median technique survival for the
CAPDP-1 group was 102 months (range 30 to 128 months)
while the median technique survival for the CAPDP-2 group
was not affected (more than 50% of the patients in the
CAPDP-2 group had functional peritoneal membrane and
catheter at the end of the follow-up).
Predictors of patients survival are shown in Table 6. By
Cox proportional hazards analysis, duration of dialysis, se-
rum triglyceride and cardiovascular score were found to be
independent predictors of overall patient survival.
Predictors of technique survival are shown in Table 7.
By Cox proportional hazards analysis, only duration of di-
alysis was found to be an independent predictor of overall
technique survival.
Discussion
In the present study, we compare the long-term effects
of conventional glucose-based PD solutions and a new, neu-
tral bicarbonate-/lactate-based PD solutions with lower level
of glucose degradation products and lower concentration of
Ca2+ on some markers of MIA syndrome and CAPD patients
and the techique survival. This study showed a statistically
significantly higher chronic inflammation, malnutrition and
cardiovascular morbidity rate in patients treated by bioin-
compatible than patients treated by biocompatible dialysis
solution. Mortality data revealed a similar 2-year-survival in
both groups. However, with time patients who underwent
CAPD by bioincompatible PD solutions had significantly
worse survival than those on CAPD with biocompatible so-
lutions. Although there was a trend toward better technique
survival in the patients on CAPD by biocompatible solutions,
a significant difference between the CAPDP groups was not
confirmed by our study. Cox proportional hazards analysis
confirmed that the duration of dialysis, serum triglyceride
and cardiovascular morbidity score were independent pre-
dictors of overall patient survival, while the duration of di-
alysis was only independent predictor of overall technique
survival.
Inspite big technical improvements during the last 20
years, morbidity and mortality rate of patients undergoing
CAPD is still very high. Recent studies suggest that, during
Table 5
Clinical outcomes for the examined patients
The examined groupsThe observed parameters CAPDP-1 CAPDP-2 p value
Follow-up duration (months),  median 78 128
Clinical outcomes, n (%)
    remained alive on CAPD 3 (14.3) 7 (33.3)
    transplanted 1 (4.8) 0 (0)
    transferred to HD and stayed alive 5 (23.8) 4 (19.0)
    died 12 (57.1) 10 (47.7)
NS
Cardiovascular causes of death, n (%)             7 (58.3)                               8 (80.0)
    ishemic heart disease 6 (50.0) 4 (40.0)
    cerebrovascular disease 1 (8.3) 2 (20.0)
    peripheral vascular disease 0 (0) 2 (20.0)
NS
Non-cardiovascular causes of death, n (%)              5 (41.7)                              2 (20.0)
    peritonitis 2 (16.7) 1 (10.0)
    multiorgan failure 3 (25.0) 1 (10.0) NS
CAPDP-1– the group of patients treated by bioincompatible peritoneal dialysis solutions; CAPDP-2 – the group of patients treated by biocompatible peritoneal
dialysis solutions; HD – hemodialysis; NS – not significant
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Fig. 1 – Kaplan-Meier survival curves for peritoneal dialysis
patients treated by biocompatible and bioincompatible
peritoneal dialysis solutions (Log- Rank; p = 0.0345).
Fig. 2 – Kaplan-Meier survival curves of technique survival
using biocompatible and bioincompatible peritoneal dialyis
solutions (Log-Rank; p = 0.0719).
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Table 6
Univariate and multivariate Cox regression model on patient survival for the overall group of patients
Univariate Multivariate
Parameters
RR (95%CI) Significance RR (95%CI) Significance
PD solutions biocompati-
bility 0.403 (0.167–0.976) 0.044* 0.761 (0.283–2.048) 0.588
Gender 1.703 (0.715–4.056) 0.229 / /
Average age 0.998 (0.973–1.023) 0.865 / /
Duration of dialysis 0.568 (0.415–0.776) 0.000* 0.457 (0.307–0.680) 0.000*
C-reactive protein 1.105 (0.987–1.238) 0.083 / /
Serum cholesterol 1.318 (0.942–1.842) 0.107 / /
Serum triglycerides 1.382 (1.035–1.844) 0.028* 1.450 (1.067–1.969) 0.018*
Serum albumin 0.946 (0.850–1.053) 0.312 / /
Cystatin C 1.103 (0.806–1.509) 0.539 / /
Residual diuresis 1.012 (0.537–1.907) 0.971 / /
Effluent IL6 0.997 (0.992–1.003) 0.327 / /
Effluent CA-125 1.012 (0.997–1.028) 0.110 / /
Peritoneal transport 1.006 (0.724–1.399) 0.969 / /
Ultrafiltration volumen 1.000 (0.999–1.001) 0.889 / /
Eject fraction 0.994 (0.940–1.050) 0.828 / /
Presence  of LVH 0.738 (0.297–1.838) 0.514 / /
Presence of VC 1.993 (0.829–4.794) 0.123 / /
IMT 0.434 (0.138–1.366) 0.153 / /
Carotid narrowing degree 1.013 (0.994–1.033) 0.189 / /
Presence of calcified
plaques 0.959 (0.350–2.627) 0.935 / /
BMI 0.963 (0.765–1.213) 0.748 / /
MAC 0.909 (0.739–1.116) 0.361 / /
MAMC 0.989 (0.804–1.217) 0.916 / /
SGA 1.491 (0.985–2.259) 0.059 / /
CVS 1.448 (1.058–1.981) 0.021* 2.095 (1.362–3.223) 0.001*
CI – confidence interval; RR – relative risk;* statistically significant; LVH – left ventricular hypertrophy; VC – valvular calcification;
IMT – intima-media thickness; BMI – body mass index; MAC – mid-arm circumference; MAMC – mid-arm muscle circumference;
CVS – cardiovascular score
Table 7
Univariate and multivariate Cox regression model on techique survival for overall group of patients
Univariate Multivariate
Parameters
RR (95%CI) Significance RR (95%CI) Significance
PD solutions biocompatibility 0.342 (0.099–1.184) 0.090 / /
Gender 0.902 (0.237–3.432) 0.880 / /
Average age 0.985 (0.952–1.020) 0.409 / /
Duration of dialysis 0.598 (0.404–0.886) 0.010* 0.598 (0.404–0.886) 0.010*
C-reactive protein 1.095 (0.949–1.264) 0.216 / /
Serum cholesterol 1.005 (0.631–1.598) 0.985 / /
Serum triglycerides 0.921 (0.579–1.465) 0.727 / /
Serum albumin 0.969 (0.828–1.135) 0.699 / /
Serum cystatin C 1.193 (0.770–1.848) 0.431 / /
Residual diuresis 0.920 (0.368–2.299) 0.859 / /
Effluent IL6 0.971 (0.829–1.139) 0.720 / /
Effluent Ca125 0.999 (0.991–1.006) 0.726 / /
Peritoneal transport 0.821 (0.592–1.138) 0.236 / /
Ultrafiltration volumen 0.993 (0.969–1.019) 0.601 / /
Eject fraction 0.984 (0.918–1.056) 0.663 / /
Presence  of LVH 0.826 (0.241–2.830) 0.761 / /
Presence of VC 0.819 (0.233–2.881) 0.756 / /
IMT 2.023 (0.546–7.498) 0.292 / /
Carotid narrowing degree 0.996 (0.967–1.026) 0.791 / /
Presence of calcified plaques 1.269 (0.335–4.802) 0.726 / /
BMI 1.248 (0.941–1.653) 0.124 / /
MAC 1.317 (0.459–3.775) 0.608 / /
MAMC 1.224 (0.908–1.650) 0.185 / /
SGA 1.141 (0.568–2.293) 0.712 / /
CVS 0.860 (0.581–1.273) 0.451 / /
CI – confidence interval; RR –  relative risk;* statistically significant; LVH – left ventricular hypertrophy; VC – valvular calcification;
IMT – intima media thickness; BMI – body mass index;  MAC – mid-arm circumference; MAMC – mid-arm muscle circumference;
CVS – cardiovascular score
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the first 2 years of follow-up, the survival rate of patients
with chronic kidney disease who begin PD is the same as or
better than those who begin HD. However, the majority of
these studies show higher mortality rates in PD during the
second year and thereafter 27, 28. Different risk factors were
reported to be important for outcome of patient on CAPD:
age and race, underlying disease (diabetes), residual renal
function, MIA syndrome and peritoneal membrane charac-
teristics.
In general, age and the presence of diabetes at the be-
ginning of the treatment are the main factors associated with
coronary artery calcifications and mortality in dialysis pa-
tients 13, 28, 29. Chow et al. 30 reported that diabetes mellitus
was the strongest risk factor for sudden death after account-
ing for other cardiovascular and relevant risk factors. In our
study, the age and the prevalence of diabetes mellitus were
similar in both groups.
Residual renal function (RRF) during the first years of
PD is an important factor of PD adequacy, contributing of
20%–50% a total solute clearance. In a recent reanalysis of
the CANUSA study, there is clear evidence indicating higher
contribution of RRF to the clinical outcomes of PD patients
than peritoneal clearance. Namely, patients with RRF had
better survival than those without 31. Williams et al. 32 and
Haag-Weber et al. 33 showed urine volume higher in patients
treated with the new biocompatible PD solutions. Szeto et
al. 34 analyzed the effect of the biocompatible PD solution
(balance) in 25 randomized patients and found out the bene-
ficial effect of those solutions on membrane characteristics
and CRP; however, there were no differences between con-
ventional and bicompatible solution concerning daily ultra-
filtration and urine volume. Our patients had preserved RRF
at the start of CAPD without a significant difference between
the groups during the treatment (data not showen). Still, the
contribution of a diminished ultrafiltration and subclinical
fluide overload remains unexplored and may influence RRF
in patients treated with biocompatible solutions 35.
Chronic inflammation may also play a major role in
high cardiovascular mortality rate in CAPD patients 36. Ap-
proximately 30%–50% of non-dialysis, hemodialysis and
peritoneal dialysis patients had a state of chronic inflamma-
tion as defined by increased biochemical markers of the
acute-phase response, including CRP or proinflammatory
cytokines 37. Components of dialysis solutions, especially
GDPs, damage peritoneal cells and may trigger an inflam-
matory response. The use of a more biocompatible, neutral
pH PD solution with a low concentration of GDPs was
shown to result in significant reduction of intraperitoneal in-
flammation 32, 38, 39. However, the study by Pejek et al. 40
showed no difference between a conventional solution (Di-
aneal) and a more biocompatible solution (Physioneal) in ef-
fluent macrophage inflammatory activation after a timed
overnight dwell. Also, the systemic levels of IL-6 and hs-
CRP did not differ between the two solutions 33, 40. In our
groups of patients, mean value of serum hs-CRP was signifi-
cantly lower in the patients who underwent CAPD by bio-
compatible PD solutions than in the patients on CAPD
treated with bioincompatible solutions, while parameters of
local inflammation were similar between the CAPD groups.
These findings are in agreement with our previous results
that confirmed no difference in cytokines levels in patients
treated with different PD solutions 41.
Protein energy malnutrition and muscle wasting are
present in many patients with chronic renal failure and sig-
nificantly influence patients outcome. This may be a conse-
quence of uremia per se or related to co-morbid condi-
tions 42.  Also, many studies report that inflammation may be
an important cause of malnutrition 43. Qureshi et al. 44
showed elevated serum CRP not only associated with hypo-
albuminemia, but also more commonly with in malnourished
patients as assessed by SGA of nutritional status. Zheng et
al. 45 observed that GDPs in the PD solution are probably in-
volved in the suppression of appetite and that the degree of
inhibition is proportional to pH and glucose concentration.
All our patients had similar values of serum total cholesterol,
triglycerides, albumin and BMI. However, the mean values
of mid-arm circumference, mid-arm muscle circumference
and subjective global assessment were significantly better in
the patients treated with biocompatible solutions than the pa-
tients on CAPD with bioincompatible solutions. This means
that chronic peritoneal dialysis with bioincompatible solu-
tions may influence muscle wasting.
The results of studies that evaluated the effects of novel
more biocompatible solutions on peritoneal ultrafiltration
(UF) rate and peritoneal solute transport are conflicting 46, 47.
These studies did not show that biocompatibility of PD solu-
tions had significant influence on peritoneal UF rate and sol-
ute transport characteristics in a selected group of patients.
Cardiovascular complications are the major causes of
morbidity and mortality in PD patients mainly due to cardio-
vascular calcifications and progressive atherosclerosis 4–13. The
present study shows a high overall cardiovascular morbidity
rate in both groups of patients with statistically significant
differences in the presence of LVH, all parameters of pe-
ripheral vascular disease and cardiovascular score between
the groups. Since there were no differences between the
groups in the incidence of diabetes, hypertension, ultrafil-
tration volume and medication, it is possible that biocom-
patible PD solutions might have beneficial effects on car-
diovascular morbidity. Still, there may be numerous addi-
tional factors that may influence cardiovascular parameters
including subclinical overhydration and others not included
in this study.
In Western countries, cardiovascular disease is a lead-
ing cause of mortality in dialysis patients 6, 48, 49. Lee et al. 50
reported that infectious disease was the leading cause of
mortality for dialysis patients and caused significantly more
mortality in HD than in PD patients. In our study, the most
frequent causes of death were cardiovascular diseases in both
groups without statistically significant difference.
Our study presents a better patients survival rate using
biocompatible PD solutions and similar or worse long-term
patients survival rate using bioincompatible PD solutions
than in several reports 2, 51–56. One of the explanations of
better results in our study could be a small number of the se-
lected groups and elimination of patients with severe comor-
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bidity (see excluding criteria in the section Methods) and
using evidently better biocompatible CAPD solutions.
This study also presents the better overall technique
survival rate than in several reports 2, 48, 51–56. Thus, 1-, 2-, and
3-year technique survival rates were 86.0%, 73.6% and
60.5%, respectively, for Korean, and 89.%, 65.9% and
51.9%, respectively, for Swedish patients 2. In our patients,
1-, 2- and 3-year technique survival rates were: in the
CAPDP-1 group 100%, 90.5%, 80.9%, respectively, and in
the CAPDP-2 group 100% for all the three periods. Even so,
the difference between the groups did not reach a statistical
significance and one of the explanations could be the small
number of patients in both groups. Long-term technique sur-
vival on CAPD by bioincompatible PD solutions was ad-
dressed by many authors, but there were no studies to con-
firm the effects of new biocompatible PD solutions on the
technique and patients survival after a follow-up period of
more than two years 22. In our study we analyzed the effects
of new, neutral PD solutions on the technique and patients
survival after a follow-up period of up to 12 years.
By Cox proportional hazards analysis we showed dura-
tion of dialysis, serum triglyceride and cardiovascular score
to be independent predictors of overall patients survival.
Only duration of dialysis was found to be independent pre-
dictor of overall technique survival.
The present study has to be interpreted in the light of
several weak points. The study population included patients
with military insurance and those with civil one. Although
there were no significant differences between them, one may
raise the question about selection bias. Cross-sectional analy-
sis of potentional risk factors does not provide more dynamic
data that may change with the time on CAPD. A small num-
ber of patients may influence statistical significance and we
believe that inclusion of a higher number of patients may
contribute to the final conclusion. Apart from those pre-
sented, there may be more parameters not included in this
study that could reveal the effects of biocompatibility of PD
solution on parameters of MIA syndrome and patients and
technique survival.
Conclusion
Patients undergoing CAPD have high cardiovascular
morbidity. Chronic inflammation revealed by hs-CRP, pro-
tein energy malnutrition and peripheral atherosclerosis had
higher prevalence in those treated by bioincompatible PD
solutions. Patients survival after a 2-year-follow-up is sig-
nificantly better if patients treated by biocompatible solu-
tions. No difference in the technique survival is observed
between the groups of our patients at any point of time.
Although patients treated with biocompatible solutions
showed a significantly better survival, Cox regression analy-
sis did not confirm that biocompatibility of PD solutions was
independent predictor of patients and the technique survival.
In our setting, duration of dialysis, serum triglyceride
and cardiovascular score significantly predicted an overall
CAPD patients survival, while duration of dialysis was found
to be the only independent predictor of overall technique
survival. Further well designed and controlled studies on
higher number of patients are needed to highlight the role of
biocompatibility in outcome of patients on chronic peritoneal
dialysis.
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